is pleased to advise that the Company has filed a Pre-Investigation New Drug Application (‘preIND’) meeting request with the US Food and Drug Administration (‘FDA’) for EmtinB for treatment of advanced glaucoma in adults. Dr Keating was first appointed as Director of the Company on 5 December 2023 and is an experienced entrepreneur and CEO having co-founded and led ResApp Health from start-up to its ultimate acquisition by Pfizer for $180 million.
